Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 3/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA4 | P22748 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029298 | 1.00 | LMNA (0.54) | LMNAGAAF2PRSS1PRSS2 | |
| SCHEMBL3528429 | 0.81 | LMNA (0.54) | LMNAGAAALDH1A1BCAT1 | |
| SCHEMBL3528433 | 0.81 | LMNA (0.54) | LMNAGAAALDH1A1BCAT1 | |
| SCHEMBL7673667 | 0.80 | LMNA (0.71) | LMNAGAAF2PRSS1PRSS2 | |
| SCHEMBL7673670 | 0.80 | LMNA (0.71) | LMNAGAAF2PRSS1PRSS2 | |
| SCHEMBL4972178 | 0.79 | LMNA (0.70) | LMNAGAAALDH1A1BCAT1 | |
| SCHEMBL4110091 | 0.79 | LMNA (0.70) | LMNAGAAALDH1A1BCAT1 | |
| SCHEMBL2439782 | 0.77 | LMNA (0.58) | LMNAGAAF2PRSS1PRSS2 | |
| SCHEMBL2439780 | 0.77 | LMNA (0.58) | LMNAGAAF2PRSS1PRSS2 | |
| SCHEMBL7613335 | 0.76 | LMNA (0.65) | LMNAGAACA2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322602-A1 | SUBSTITUTED CINNAMIC ACID GUANIDIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND TO A MEDICAMENT CONTAINING THESE COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-6399824-B1 | FOR THERAPY AND PROPHYLAXIS OF ARRHYTHMIAS, CARDIAC INFRACTION, ISCHEMIC CONDITIONS, ANGINA PECTORIS, SHOCK, FOR PRESERVING AND STORING A TRANSPLANT FOR SURGICAL MEASURE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-04 | — | — | US | disclosed |
| US-20020058710-A1 | SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2002-05-16 | — | — | US | disclosed |
| WO-2002024637-A1 | SUBSTITUTED CINNAMIC ACID GUANIDIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND TO A MEDICAMENT CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058710-A1 | SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM | GANC, GMPS, GCDH | LMNA 431/4885GAA 11/4885F2 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.